Population pharmacokinetic and pharmacogenetic analysis of 6‐mercaptopurine in paediatric patients with acute lymphoblastic leukaemia

Abstract

The developed pharmacokinetic model (if successful at external validation) would offer a more rational dosing approach for 6-MP than the traditional empirical method since it combines the current practice of using body surface area in 6-MP dosing with a pharmacogenetically guided dosing based on TPMT genotype.